Methionine Adenosyltransferase α2 Sumoylation Positively Regulate Bcl-2 Expression in Human Colon and Liver Cancer Cells

Overview

Journal Oncotarget

Specialty Oncology

Date 2015 Sep 30

PMID 26416353

Citations 20

Authors

Maria Lauda Tomasi

Minjung Ryoo

Komal Ramani

Ivan Tomasi

Pasquale Giordano

Jose M Mato

Shelly C Lu

Affiliations

Soon will be listed here.

Abstract

Ubiquitin-conjugating enzyme 9 (Ubc9) is required for sumoylation and inhibits apoptosis via Bcl-2 by unknown mechanism. Methionine adenosyltransferase 2A (MAT2A) encodes for MATα2, the catalytic subunit of the MATII isoenzyme that synthesizes S-adenosylmethionine (SAMe). Ubc9, Bcl-2 and MAT2A expression are up-regulated in several malignancies. Exogenous SAMe decreases Ubc9 and MAT2A expression and is pro-apoptotic in liver and colon cancer cells. Here we investigated whether there is interplay between Ubc9, MAT2A and Bcl-2. We used human colon and liver cancer cell lines RKO and HepG2, respectively, and confirmed key finding in colon cancer specimens. We found MATα2 can regulate Bcl-2 expression at multiple levels. MATα2 binds to Bcl-2 promoter to activate its transcription. This effect is independent of SAMe as MATα2 catalytic mutant was also effective. MATα2 also directly interacts with Bcl-2 to enhance its protein stability. MATα2's effect on Bcl-2 requires Ubc9 as MATα2's stability is influenced by sumoylation at K340, K372 and K394. Overexpressing wild type (but not less stable MATα2 sumoylation mutants) protected from 5-fluorouracil-induced apoptosis in both colon and liver cancer cells. Colon cancer have higher levels of sumoylated MATα2, total MATα2, Ubc9 and Bcl-2 and higher MATα2 binding to the Bcl-2 P2 promoter. Taken together, Ubc9's protective effect on apoptosis may be mediated at least in part by sumoylating and stabilizing MATα2 protein, which in turn positively maintains Bcl-2 expression. These interactions feed forward to further enhance growth and survival of the cancer cell.

Citing Articles

S-Adenosylmethionine: A Multifaceted Regulator in Cancer Pathogenesis and Therapy.

Fernandez-Ramos D, Lopitz-Otsoa F, Lu S, Mato J Cancers (Basel). 2025; 17(3).

PMID: 39941901 PMC: 11816870. DOI: 10.3390/cancers17030535.

The role of forkhead box M1-methionine adenosyltransferase 2 A/2B axis in liver inflammation and fibrosis.

Yang B, Lu L, Xiong T, Fan W, Wang J, Barbier-Torres L Nat Commun. 2024; 15(1):8388.

PMID: 39333125 PMC: 11436801. DOI: 10.1038/s41467-024-52527-8.

SUMOylation controls Hu antigen R posttranscriptional activity in liver cancer.

Lachiondo-Ortega S, Rejano-Gordillo C, Simon J, Lopitz-Otsoa F, C Delgado T, Mazan-Mamczarz K Cell Rep. 2024; 43(3):113924.

PMID: 38507413 PMC: 11025316. DOI: 10.1016/j.celrep.2024.113924.

Sumoylation of methionine adenosyltransferase alpha 1 promotes mitochondrial dysfunction in alcohol-associated liver disease.

Floris A, Chandla S, Lim Y, Barbier-Torres L, Seth K, Khangholi A Hepatology. 2023; 80(1):102-118.

PMID: 38100286 PMC: 11178676. DOI: 10.1097/HEP.0000000000000717.

Role of non-canonical post-translational modifications in gastrointestinal tumors.

Liu Y, Liu J, Peng N, Hai S, Zhang S, Zhao H Cancer Cell Int. 2023; 23(1):225.

PMID: 37777749 PMC: 10544213. DOI: 10.1186/s12935-023-03062-x.

References

Saitoh H, Hinchey J . Functional heterogeneity of small ubiquitin-related protein modifiers SUMO-1 versus SUMO-2/3. J Biol Chem. 2000; 275(9):6252-8. DOI: 10.1074/jbc.275.9.6252. View

Hakimi M, PRIVAT I, Valay J, Lerbs-Mache S . Evolutionary conservation of C-terminal domains of primary sigma(70)-type transcription factors between plants and bacteria. J Biol Chem. 2000; 275(13):9215-21. DOI: 10.1074/jbc.275.13.9215. View

Buschmann T, Fuchs S, Lee C, Pan Z, Ronai Z . SUMO-1 modification of Mdm2 prevents its self-ubiquitination and increases Mdm2 ability to ubiquitinate p53. Cell. 2000; 101(7):753-62. DOI: 10.1016/s0092-8674(00)80887-9. View

Catz S, Johnson J . Transcriptional regulation of bcl-2 by nuclear factor kappa B and its significance in prostate cancer. Oncogene. 2001; 20(50):7342-51. DOI: 10.1038/sj.onc.1204926. View

Pascale R, Simile M, De Miglio M, Muroni M, Calvisi D, Asara G . Cell cycle deregulation in liver lesions of rats with and without genetic predisposition to hepatocarcinogenesis. Hepatology. 2002; 35(6):1341-50. DOI: 10.1053/jhep.2002.33682. View

Gill G . Post-translational modification by the small ubiquitin-related modifier SUMO has big effects on transcription factor activity. Curr Opin Genet Dev. 2003; 13(2):108-13. DOI: 10.1016/s0959-437x(03)00021-2. View

Johnson E . Protein modification by SUMO. Annu Rev Biochem. 2004; 73:355-82. DOI: 10.1146/annurev.biochem.73.011303.074118. View

Issa J, Ottaviano Y, Celano P, Hamilton S, Davidson N, Baylin S . Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon. Nat Genet. 1994; 7(4):536-40. DOI: 10.1038/ng0894-536. View

Mo Y, Yu Y, Theodosiou E, Ee P, Beck W . A role for Ubc9 in tumorigenesis. Oncogene. 2005; 24(16):2677-83. DOI: 10.1038/sj.onc.1208210. View

10.

Klenk C, Humrich J, Quitterer U, Lohse M . SUMO-1 controls the protein stability and the biological function of phosducin. J Biol Chem. 2006; 281(13):8357-64. DOI: 10.1074/jbc.M513703200. View

11.

Lu Z, Wu H, Mo Y . Regulation of bcl-2 expression by Ubc9. Exp Cell Res. 2006; 312(10):1865-75. DOI: 10.1016/j.yexcr.2006.02.017. View

12.

Wang L, Brown S . BindN: a web-based tool for efficient prediction of DNA and RNA binding sites in amino acid sequences. Nucleic Acids Res. 2006; 34(Web Server issue):W243-8. PMC: 1538853. DOI: 10.1093/nar/gkl298. View

13.

Adams J, Cory S . The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene. 2007; 26(9):1324-37. PMC: 2930981. DOI: 10.1038/sj.onc.1210220. View

14.

Handayani T, Sakinah S, Nallappan M, Lope Pihie A . Regulation of p53-, Bcl-2- and caspase-dependent signaling pathway in xanthorrhizol-induced apoptosis of HepG2 hepatoma cells. Anticancer Res. 2007; 27(2):965-71. View

15.

Prabhudesai S, Rekhraj S, Roberts G, Darzi A, Ziprin P . Apoptosis and chemo-resistance in colorectal cancer. J Surg Oncol. 2007; 96(1):77-88. DOI: 10.1002/jso.20785. View

16.

Chen H, Xia M, Lin M, Yang H, Kuhlenkamp J, Li T . Role of methionine adenosyltransferase 2A and S-adenosylmethionine in mitogen-induced growth of human colon cancer cells. Gastroenterology. 2007; 133(1):207-18. DOI: 10.1053/j.gastro.2007.03.114. View

17.

Geiss-Friedlander R, Melchior F . Concepts in sumoylation: a decade on. Nat Rev Mol Cell Biol. 2007; 8(12):947-56. DOI: 10.1038/nrm2293. View

18.

Yang H, Iglesias Ara A, Magilnick N, Xia M, Ramani K, Chen H . Expression pattern, regulation, and functions of methionine adenosyltransferase 2beta splicing variants in hepatoma cells. Gastroenterology. 2007; 134(1):281-91. PMC: 2409110. DOI: 10.1053/j.gastro.2007.10.027. View

19.

Ramani K, Yang H, Xia M, Iglesias Ara A, Mato J, Lu S . Leptin's mitogenic effect in human liver cancer cells requires induction of both methionine adenosyltransferase 2A and 2beta. Hepatology. 2007; 47(2):521-31. PMC: 2387125. DOI: 10.1002/hep.22064. View

20.

Yip K, Reed J . Bcl-2 family proteins and cancer. Oncogene. 2008; 27(50):6398-406. DOI: 10.1038/onc.2008.307. View